FDA to Review Roflumilast Foam for Seborrheic Dermatitis FDA to Review Roflumilast Foam for Seborrheic Dermatitis

If approved, the once-daily foam would be the first topical drug with a new mechanism of action for seborrheic dermatitis in more than two decades.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news